Oppenheimer Asset Management Inc. buys 8,800 shares of BeiGene, Ltd. (NASDAQ:BGNE)

Oppenheimer Asset Management Inc. raised its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE ​​​​– Free Report) by 48.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,924 shares of the company’s stock after buying an additional 8,800 shares during the quarter. The holdings of Oppenheimer Asset Management Inc. holdings in BeiGene were worth $3,841,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Jump Financial LLC bought a new position in shares of BeiGene in the 4th quarter valued at approximately $354,000. Dynamic Technology Lab Private Ltd bought a new position in BeiGene in the fourth quarter valued at $215,000. BI Asset Management Fondsmaeglerselskab AS bought a new position in BeiGene in the fourth quarter valued at $183,000. Trexquant Investment LP purchased a new position in shares of BeiGene in the fourth quarter valued at $1,098,000. Finally, BNP Paribas Asset Management Holding SA grew its position in shares of BeiGene by 7.4% in the fourth quarter. BNP Paribas Asset Management Holding SA now owns 102,970 shares of the company’s stock worth $18,572,000 after purchasing an additional 7,130 shares during the period. Institutional investors own 48.55% of the company’s shares.

BeiGene trading down 1.0%

Shares of BGNE stock opened at $196.45 on Tuesday. The stock has a market cap of $19.04 billion, a P/E ratio of -25.95 and a beta of 0.61. BeiGene, Ltd. has a 1 year low of $126.97 and a 1 year high of $215.00. The company has a current ratio of 1.98, a quick ratio of 1.75, and a debt-to-equity ratio of 0.06. The stock has a 50-day simple moving average of $178.20 and a 200-day simple moving average of $163.51.

BeiGene (NASDAQ:BGNE ​​- Get Your Free Report ) last released its earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $1.12. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The firm had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. During the same period in the previous year, the company posted EPS of ($3.64). The company’s revenue was up 56.1% compared to the same quarter last year. On average, research analysts predict that BeiGene, Ltd. will post -5.13 earnings per share for the current fiscal year.

Analyst upgrades and downgrades

BGNE has been the subject of a number of research reports. JPMorgan Chase & Co. upped their target price on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Citigroup upped their target price on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Bank of America cut their price target on BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $233.42.

See the latest stock report on BGNE

Insider buying and selling

In other BeiGene news, COO Xiaobin Wu sold 5,556 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The transaction was disclosed in a filing with the SEC, which can be accessed via this link. In other news, CEO John Oyler sold 2,789 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $159.58, for a total transaction of $445,068.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Also, COO Xiaobin Wu sold 5,556 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40. The disclosure for this sale can be found here. Insiders sold 13,210 shares of company stock worth $2,269,721 in the last quarter. 7.43% of shares are owned by company insiders.

BeiGene profile

(Free report)

BeiGene, Ltd., through its subsidiaries, is engaged in the development and commercialization of oncology drugs worldwide. Its products include BRUKINSA for treating various blood cancers; TEVIMBRA to treat various solid tumors and blood cancers; PARTRUVIX for the treatment of various solid malignant tumors; XGEVA for treating bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO for treating acute lymphoblastic leukemia; KYPROLIS for the treatment of R/R multiple myeloma; REVLIMID for treating multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric Castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, for treating breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advanced renal cell carcinoma; AFINITOR for advanced renal cell carcinoma, NET, SEGA and breast cancers; and ZYKADIA to treat ALK + NSCLC.

Featured stories

Want to see what other hedge funds BGNE owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNE ​​- Free Report).

Get news and reviews for BeiGene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BeiGene and related companies with MarketBeat.com’s FREE daily email newsletter.